Updated:
Insud Pharma
Insud Pharma is a global pharmaceutical group with 10,000 professionals, 21 plants, and 15 R&D centers operating across more than 50 countries.
Insud Pharma
Insud Pharma was founded more than 45 years ago as a pharmaceutical group headquartered in Madrid, Spain. It operates as a vertically integrated manufacturer covering active pharmaceutical ingredients (APIs), finished dosage forms (FDFs), and branded medicines for human and animal health (per firm website). The firm's strategy spans the full pharmaceutical value chain: research and development, manufacturing, and commercialization. It maintains 15 R&D centers and 21 industrial plants globally. Insud Pharma offers CDMO (contract development and manufacturing organization) and CMO services, producing high-quality APIs and FDFs across diverse therapeutic areas. Its geographic footprint includes Europe, the Americas, and Asia, with offices in Madrid, Bentonville, New York, Cambridge, Chicago, San Mateo, and Woburn (per firm website). Insud Pharma employs over 10,000 professionals worldwide and operates in more than 50 countries. The group has not disclosed a specific founding year, AUM, or named principals publicly. No recent operational events from the last 24 months were available in sourced materials. Unlike a traditional family office, Insud Pharma is structured as an operating pharmaceutical company rather than an investment vehicle. Its distinct model lies in owning and operating manufacturing plants and R&D centers globally, functioning as both a producer of its own branded medicines and a service provider to other pharmaceutical firms through its CDMO/CMO arm. This gives it a dual revenue stream: proprietary drug sales and contract manufacturing fees.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Spain
City
Madrid
Corporate office
Madrid, Spain
Additional offices
Bentonville, USA · New York, USA · Cambridge, USA · Chicago, USA · San Mateo, USA · Woburn, USA · Spain
Sector focus
Frequently asked questions
Who runs investment decisions at Insud Pharma?
Insud Pharma does not publicly disclose specific principals or investment decision-makers on its website. The company presents itself as a corporate pharmaceutical group rather than an investment firm, so leadership likely resides with executive management, but their identities are not named in available sources.
Is Insud Pharma structured as a single family office or does it operate more like a pharmaceutical firm?
Insud Pharma operates as an active pharmaceutical operating company, not as a family office or an investment vehicle. It owns manufacturing plants, R&D centers, and sells branded medicines plus CDMO/CMO services. There is no public indication that it functions as a traditional single or multi-family office.
What investment stages does Insud Pharma typically target?
Insud Pharma does not publicly disclose investment stage preferences. Its operational model involves direct ownership of industrial assets — 21 manufacturing plants and 15 R&D centers — and ongoing commercial activities across the pharmaceutical value chain, rather than external investment stages.
Which sectors does Insud Pharma explicitly avoid?
Insud Pharma does not publish a list of avoided sectors. Based on its public profile, it focuses exclusively on pharmaceuticals and biotech for human and animal health, with no stated exclusions beyond those implied by its therapeutic-area offerings.
Does Insud Pharma maintain philanthropic structures, and how are they separated?
The firm's website includes sections on sustainability, corporate social responsibility (RSC), and news, but no specific philanthropic foundations or vehicles are named in public materials. The separation of charitable activities from commercial operations is not detailed.
Where does the underlying wealth come from for Insud Pharma?
Insud Pharma does not disclose the origin of its underlying wealth. The company is presented as an established pharmaceutical group, but no information about its founding capital or ownership individuals is publicly available.
What is Insud Pharma's known posture on co-investments alongside external GPs?
Insud Pharma does not publicly discuss co-investments with external general partners. Its business model centers on vertical integration and contract manufacturing, not fund-based investing or partnership deals with financial sponsors.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: